FX.co ★ Pfizer Reports Positive Topline Data From Phase 3 TALAPRO-2 Study Of Talzenna Plus Xtandi

Pfizer Inc. (PFE) announced favorable top-line outcomes from the Phase 3 TALAPRO-2 trial involving the use of Talzenna together with Xtandi for individuals suffering from metastatic castration-resistant prostate cancer (mCRPC) on Thursday. The findings from this study revealed that the combination of Talzenna and Xtandi significantly improved overall survival (OS) in mCRPC patients compared to treatment with Xtandi alone. The U.S. Food and Drug Administration (FDA) has already sanctioned the use of Talzenna and Xtandi together for adult patients with HRR gene-mutated mCRPC. This combination therapy has also received approval from the European Commission for mCRPC patients for whom chemotherapy is not deemed clinically necessary.